

Freedonia Focus Reports  
World Collection



# World Personalized Medicine Tests for Cancer

January 2017



## Highlights

### World Overview and Forecasts

Introduction | Technologies Used | Test Targets | Products on the Market | Demand

### Regional Segmentation and Forecasts

Regional Demand Overview

### Industry Structure

Industry Characteristics

### Resources

CLICK TO ORDER  
FULL REPORT  
**BROCHURE**  
CLICK TO ORDER  
FULL REPORT

[www.freedoniafocusreports.com](http://www.freedoniafocusreports.com)

# TABLE OF CONTENTS

---

<b>1. Highlights</b>	<b>4</b>
<b>2. World Overview &amp; Forecasts</b>	<b>5</b>
Introduction	5
Cancer Treatments	5
Cancer Risk Assessment	6
Cancer Screening	7
Cancer Monitoring	8
Technologies Used	9
Immunoassays	9
Immunohistochemistry	9
Flow Cytometry	9
In Situ Hybridization	10
Nucleic Acid Amplification Technologies	10
Analysis of Gene Expression Patterns (Gene Signatures)	10
Microarrays	11
Sequencing Technologies	11
Mass Spectrometry	11
Liquid Biopsies	12
Information Technology	12
Test Targets	13
Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression	13
Epidermal Growth Factor Receptor	13
Kirsten Rat Sarcoma Mutations	13
BRAF Mutations	14
Uridine Diphosphate-Glucuronyl Transferase 1A1 Genetic Variants	14
5-Fluorouracil Therapy	14
Phosphatidylinositol 3-Kinase Gene Mutations	15
Kinesin-Like Protein 6 Mutations	15
Anaplastic Lymphoma Kinase Mutations	15
Products on the Market	16
Demand	17
<b>3. REGIONAL SEGMENTATION &amp; FORECASTS</b>	<b>19</b>
Regional Demand Overview	19

<b>4. Industry Structure</b>	<b>24</b>
Industry Characteristics	24
Abbott Laboratories	24
BioMérieux	24
Quest Diagnostics	25
Roche Holding	25
<b>5. About This Report</b>	<b>26</b>
Scope & Method	26
Sources	27
Industry Codes	27
Resources	28

# LIST OF TABLES & FIGURES

---

Table 1   Select Personalized Medicine Testing Products for Cancer	16
Figure 1   World Personalized Medicine Tests for Cancer Demand; 2016, 2021 (US\$ mil)	17
Table 2   World Personalized Medicine Tests for Cancer Demand; 2016, 2021 (US\$ mil)	17
Figure 2   World Personalized Medicine Tests for Cancer Demand by Region; 2016, 2021 (US\$ mil)	19
Table 3   World Personalized Medicine Tests for Cancer Demand by Region; 2016, 2021 (US\$ mil)	19
Table 4   Industry Codes Related to Personalized Medicine Tests for Cancer	27

# ABOUT THIS REPORT

---

## Scope & Method

This report forecasts total world demand in 2021 for personalized medicine tests for cancer by major world region in US dollars at the manufacturers' level. To illustrate historical trends world demand (including regional segments) is provided for 2016. Major world regions include North America, the European Union, and the rest of the world.

This report provides a market assessment, estimate, and competitive analysis for tests for oncology that use biomarkers. This analysis includes a range of technologies made by scores of companies. These types of tests have demonstrated faster revenue growth than in vitro diagnostic (IVD) broadly, and considerable interest from competitors. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis, and personalize therapy.

In this report text, the US Food and Drug Administration's (FDA) definition of "companion diagnostics" is used. Therefore, companion diagnostic tests are FDA cleared or approved (if marketed in the US), are included in prescribing information for the targeted therapy, and testing must be performed before a patient can receive that therapy. In contrast, the term "personalized medicine" is used broadly in this report text. "Personalized medicine" refers to all tests that provide information to aid physicians making a treatment decision. The focus of this report includes a wide range of applications of personalized medicine, as well as the wide range of products and test services available to meet the needs of these applications. The term "companion diagnostics market" includes both personalized and FDA-defined companion diagnostics. This report does not try to cover all aspects of the diagnostics market. Topics not included in this report include assays used for screening, diagnosis, and certain other traditional diagnostic applications.

This report quantifies trends in various measures of growth. Growth (or decline) expressed as an average annual growth rate (AAGR) is the least squares growth rate, which takes into account all available datapoints over a period. Growth calculated as a compound annual growth rate (CAGR) employs, by definition, only the first and last datapoints over a period. The CAGR is used to describe forecast growth, defined as the expected trend beginning in the base year and ending in the forecast year. Readers are encouraged to consider historical volatility when assessing particular annual values along the forecast trend, including in the forecast year.

Unless otherwise indicated, both historical and forecasted demand values are expressed in US dollars at a fixed 2015 rate of exchange with local currencies.

A full outline of report items by page is available in the Table of Contents.

## Sources

*World Personalized Medicine Tests for Cancer* (FW40068) is based on [The World Market for Personalized Medicine Tests for Cancer](#), a comprehensive industry study published by Kalorama Information in January 2017. Companies and organizations profiled in this report include both pharmaceutical and IVD companies active in the field of personalized medicine, as well as clinical laboratories that have developed their own personalized medicine assays. Thousands of IVD tests are on the market, and information from all of these tests can contribute to treatment decisions. For example, does a patient have an infectious disease, or cancer, or other disease/disorder? Results of diagnostic tests to answer these and other tests provide important information to clinicians.

Specific sources and additional resources are listed in the Resources section of this publication for reference and to facilitate further research.

## Industry Codes

Table 4 | Industry Codes Related to Personalized Medicine Tests for Cancer

NAICS/SCIAN 2007		SIC	
North American Industry Classification System		Standard Industry Codes	
325412	Pharmaceutical Preparation Mfg	2834	Pharmaceutical Preparations
325413	In-Vitro Diagnostic Substance Mfg	2835	In Vitro and In Vivo Diagnostic Substances

Source: US Census Bureau

## Copyright & Licensing

The full report is protected by copyright laws of the United States of America and international treaties. The entire contents of the publication are copyrighted by The Freedonia Group.

## Resources

### Kalorama Information

*World Market for Personalized Medicine Tests for Cancer*, January 2017

### The Freedonia Group

#### Freedonia Industry Studies

*World Medical Disposables*, August 2016

*In Vitro Diagnostic (IVD) Packaging*, June 2016

*Infection Prevention Products & Services*, April 2016

*Disposable Medical Supplies*, February 2016

*Dental Products & Materials*, January 2016

*Drug Delivery Products*, December 2015

#### Freedonia Focus Reports

*Healthcare: United States*

*Infection Prevention Products & Services: United States*

*Medical Equipment & Supplies: United States*

*Pharmaceuticals: United States*

*World Infusion Pumps*

*World Medical Devices*

*World Needle-Free Drug Delivery Systems*

#### Freedonia Custom Research

### Trade Publications

*American Journal of Infection Control*

*Drug Development & Delivery*

*Infection Control Today*

*Medical Design Technology*

*Medical Device & Diagnostic Industry*

*Medical Product Manufacturing News*

*Modern Healthcare*

### Agencies & Associations

American Cancer Society

Centers for Disease Control and Prevention

Drug Delivery Foundation

Medical Device Manufacturers Association

United States Food and Drug Administration

## ABOUT THIS REPORT

World Health Organization  
International Agency for Research on Cancer